Patents by Inventor Michael Darron ROBBINS

Michael Darron ROBBINS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER
    Publication number: 20210154183
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: January 15, 2021
    Publication date: May 27, 2021
    Inventors: Christopher Lee Mulligan, Justin Blake Bartlett, Michael Darron Robbins
  • Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer
    Patent number: 10925867
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 23, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Christopher Lee Mulligan, Justin Blake Bartlett, Michael Darron Robbins
  • Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
    Patent number: 10494433
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: December 3, 2019
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Innate Pharma
    Inventors: Pascale Andre, Mathieu Blery, Cecile Bonnafous, Ashok K. Gupta, Luisa M. Salter-Cid, Michael Darron Robbins
  • IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER
    Publication number: 20180185348
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: June 28, 2016
    Publication date: July 5, 2018
    Inventors: Christopher Lee MULLIGAN, Justin Blake BARTLETT, Michael Darron ROBBINS
  • COMBINATION OF ANTI-CS1 AND ANTI-PD1 ANTIBODIES TO TREAT CANCER (MYELOMA)
    Publication number: 20170355768
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with an anti-Programmed Death-1 (PD-1) antibody.
    Type: Application
    Filed: December 3, 2015
    Publication date: December 14, 2017
    Inventors: Michael Darron ROBBINS, Robert F. Graziano, Natalie Bezman
  • IMMUNOTHERAPEUTIC DOSING REGIMENS AND COMBINATIONS THEREOF
    Publication number: 20160264670
    Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 15, 2016
    Inventors: Robert F Graziano, Michael Darron Robbins, Maria Jure-Kunkel
  • COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMA
    Publication number: 20160257750
    Abstract: Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 8, 2016
    Inventors: Pascale ANDRE, Mathieu BLERY, Cecile BONNAFOUS, Ashok K. GUPTA, Luisa M. SALTER-CID, Michael Darron ROBBINS